Given the highly targeted nature of the cancer treatment, most Pharma companies target all their HTA activity on oncology; most, if not all, of their promotional budget on oncology spends go toward conferences and major Oncology events, which serve as the primary interface and promotional activity with target customers, decision makers, and influencers.
Not only do Pharma companies need to simultaneously invest hundreds of thousands of promotional budget dollars on competing mega-events, but they also must compete with scores of smaller events globally that the Oncology community organizes on an almost weekly basis. At the same time, extensive collaboration is needed across Commercial, Market access, and Field teams to prioritize events, focus spending, determine if executives need to attend, and find time to prepare and develop presentations.
The business case for event participation versus actual business benefits to the Oncology community should help guide that participation and spending focus.
Start with Clear Strategic Objectives
The greatest failure of oncology event participation strategy is the lack of clear, focused, and strategic objectives. This is most evident when organizations attend events for the sake of participation.
There are typically 6 objectives Pharma Commercial Teams pursue when attending events:
- New clinical data or pipeline developments are introduced, and major data announcements are made.
- KOLs and decision influencers are engaged.
- Competitor activity is monitored, and value propositions are countered with respect to peer competitors.
- Relationships with HCPs are strengthened and deepened.
- Policy and reimbursement context are understood.
- Competitor value propositions are countered.
Each event should distinctly serve one or several of the above objectives. For instance, particular small events focused on specific therapeutic/integrative areas may serve one the objectives better than others, while international major oncology congresses may serve a different primary objective.
Focused, strategic, and clear objectives drive resource allocation and utilization when attending events.
The Conference Landscape in Oncology
The oncology conference landscape is vast and complex. Major global oncology conferences attract many thousands of attendees. Smaller regional conferences may focus on particular tumor types or clinical subspecialties.
For the commercial and medical teams, planning for the upcoming year requires understanding the full spectrum of events in the oncology landscape. Assembling an event calendar such as the oncology conference calendar 2026, will allow teams to pinpoint significant events by therapeutic area, geography, and stakeholder.
This is critical for companies to establish a clear roadmap in the short-term and address the most important conferences in the long-term.
Assess Events by Value
Following the full conference landscape, the next step is event prioritization. Not every event will have a meaningful contribution for every organization, and poor conference selection may lead to a misallocation of organizational resources.
The commercial teams’ considerations for prioritization include:
- The relevance of the audience
- The number of expected attendees and the influence of the audience on the outcomes of a given event
- Possibilities for scientific presentations or symposia
- The level of competing stakeholder activity at a given event
- The relevance of geography for the company’s commercial
For instance, while a global oncology congress may appear attractive for visibility, a regional oncology congress may be more valuable for focused access to particular decision-makers and for a specific healthcare system.
Involve All Relevant Teams in Early Stage Planning
Integrating different teams is critical for developing an effective conference strategy. For most organizations, an effective commercial team relies on the medical affairs, market access, clinical development, and communications teams to manage the various pre, during, and post-event activities.
Good early alignment fosters a unified understanding of the objectives for each conference, as well as the roles of the various teams involved. For example:
- The Medical Affairs team leads scientific debates and investigator outreach.
- The Commercial teams focus on building relationships and gleaning market insights.
- The Market Access team captures pertinent policy discussions and payer viewpoints.
Coordinated efforts among these teams make for more clever and cohesive participation at conferences.
Plan for Engagement That Goes Beyond the Booth
While exhibition stalls may be the most prominent feature at many conferences, true engagement happens far beyond these official display areas. Many pharmaceutical companies have started focusing on more holistic engagement strategies that aim to reach as many contact points as possible.
Some examples include:
- Holding advisory boards with KOLs
- Organizing satellite symposia or teaching sessions
- Setting up private meetings with healthcare leaders
- Networking with stakeholders
Such engagement often yields better insights and more meaningful relationships than traditional promo activities.
Well-thought-out engagements allow teams to maximize the return for their investment for each conference.
Incorporate Digital and Hybrid Opportunities
The conference landscape has changed, and many events are now offering hybrid participation modes. Digital platforms have evolved to allow companies to engage audiences beyond those who are physically present.
The pharma teams can use these digital platforms by:
- Sharing conference insights internally
- Engaging HCPs virtually
- Tracking Twitter chatter around the clinical data
- Delivering digital content to those who are not physically present
Strategically melding attendance and engagement on-site with digital means will greatly enhance the value that can be derived from conference participation.
Assessing Conference Value
Goals for each oncology event should consistently incorporate outcome evaluation mechanisms. Knowing the return on conference investment guides teams in adjusting their plans for the upcoming years.
Some of the metrics of interest would include:
- Number of meetings with important stakeholders
- Feedback obtained from healthcare professionals
- Engagement with presentations or sessions
- Competitive intelligence obtained from the event
Reviews done after events enable teams to identify what has worked well and what has not.
What to Expect in 2026
Conferences will continue to be important venues for the dissemination of oncology research and innovative approaches to solidifying the future of cancer care. For pharmaceutical companies, a well-thought-out event strategy balances scientific exchange with commercial objectives.
Pharma companies should be able to identify the oncology conference landscape early enough and align their cross-functional teams to ensure maximum event attendance.
With early planning, the goal of this guide is to provide pharmaceutical organizations with the tools to ensure their conference strategy is purposeful and impactful.
Conclusion
The goal of this guide is to allow organizations to move beyond the standard approach of identifying well-known events. The best strategy should incorporate the seamless collaboration of commercial, medical, and market access teams to ensure the event provides an opportunity to share knowledge, establish important connections, and obtain critical insights from the industry.
With the rapidly advancing field of oncology care, purposeful planning and reliable event resources will enhance the organization’s conference participation in 2026. Ultimately, the goal of this guide is to ensure the organization’s conference participation is beneficial and contributes to improving the care offered to cancer patients.
